LDN 1641 is a compound that has been studied for its potential therapeutic effects, particularly in the context of neurodegenerative diseases and other conditions. It is a selective inhibitor of the enzyme glycogen synthase kinase 3 (GSK-3), which plays a critical role in various cellular processes, including cell survival, proliferation, and metabolism.
Articles by others on the same topic
There are currently no matching articles.